Mandate

Vinge advises Ovako Group in connection with the acquisition of BE Group’s operations in China

June 07, 2013

Vinge has advised Ovako Group in connection with the acquisition of the entire issued share capital in BE (Shanghai) Steel Trading Co., Ltd from BE Group AB (publ). The transaction is subject to approval by the relevant public authorities in China.

Ovako is a leading European producer of engineering steel for customers in the bearing, transport and manufacturing industries. The company has 11 production sites and a number of sales companies in Europe and the USA. Sales in 2012 amounted to EUR 937 million and the company had 3,040 employees. The total production capacity is 1.3 million tonnes of steel per year. The potential acquisition is intended to accelerate Ovako’s plans to establish a service centre in China in order to support Ovako’s customers in Asia by providing specific, niche products.

Vinge’s team advising Ovako Group consisted of partner Henrik Wenckert and associate Nina Farrahi. Partner Qun Gu advised on issues relating to China and Chinese law.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025